Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2024-11-27 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司关于自愿披露公司相关检测产品获得欧盟CE认证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the voluntary disclosure of the company's diagnostic products obtaining EU CE IVDR certification. It details product names, certification numbers, intended uses, and potential impacts on the company. There are no financial statements, quarterly or annual results, or detailed financial analysis. The document is relatively short (4089 characters) and serves as an official announcement about product certification and its potential business impact, rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a report publication announcement since it contains substantive content about the certification and product details. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-11-27 Chinese
圣湘生物科技股份有限公司关于召开2024年第三季度业绩说明会的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the scheduling and details of a 2024 third quarter earnings explanation meeting (业绩说明会). It mentions the date, time, location, and participation details for the meeting, but does not contain actual financial statements or substantive financial data. It references that the company has already released the 2024 third quarter report on October 24, 2024, but this document itself is only an announcement of the upcoming earnings call/meeting. The document length is short (1522 characters) and it serves as a notice for investors to attend and ask questions. Therefore, it is not the earnings release itself, nor the full quarterly report, but an announcement related to the earnings call. According to the filing definitions, this fits best as a Call Transcript (CT) if it were the transcript, but since it is only an announcement of the meeting, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is a general regulatory announcement about the meeting and does not contain the transcript or financial data. However, since the filing definitions do not have a specific category for earnings call announcements, and the document is an announcement of the earnings explanation meeting, the best fit is Regulatory Filings (RNS).
2024-11-27 Chinese
圣湘生物科技股份有限公司2024年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from a shareholders' meeting (临时股东大会决议公告) held on November 21, 2024. It details the meeting attendance, voting results on specific proposals, and legal witness statements confirming the validity of the meeting and resolutions. There is no financial data, earnings information, or detailed report content. The document is an official announcement of voting results from a shareholders' meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is about 3,037 characters, consistent with an announcement rather than a full report.
2024-11-21 Chinese
圣湘生物科技股份有限公司关于注销部分回购股份并减少注册资本暨通知债权人的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from the company regarding the cancellation of repurchased shares and the consequent reduction of registered capital. It includes detailed information about notifying creditors, the legal basis for the action, and instructions for creditors to claim debts or request guarantees. The document references specific board and shareholder meetings approving the action and provides procedural details for creditors. This type of announcement is related to capital structure changes, specifically the cancellation of treasury shares and reduction of registered capital, which fits the category of Share Issue/Capital Change (SHA). The document is not a full financial report, earnings release, or management discussion, but a formal capital change announcement.
2024-11-21 Chinese
湖南启元律师事务所关于圣湘生物科技股份有限公司2024年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and validity of the procedures, attendance, and voting results of the 2024 second extraordinary shareholders' meeting of 圣湘生物科技股份有限公司. It details the convening, attendance qualifications, voting procedures, and results of the shareholders' meeting. The document does not contain financial statements or financial performance data, nor is it a report of financial results or management discussion. It is not an announcement of voting results alone but a legal opinion on the meeting's procedural compliance and validity. This type of document is best classified under Declaration of Voting Results & Voting Rights Announcements (DVA) because it relates to the official validation and declaration of shareholder meeting voting results and procedures, supported by legal opinion. The document length is 3403 characters, which is relatively short but contains substantive content about the meeting and voting results, not just a brief announcement or a report publication notice. Therefore, the best fit is DVA with high confidence.
2024-11-21 Chinese
圣湘生物科技股份有限公司2024年第二次临时股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as meeting materials for the "2024 Second Extraordinary General Meeting of Shareholders" of 圣湘生物科技股份有限公司. It contains detailed meeting instructions, agenda, and two specific proposals for shareholder approval: one about changing the use of repurchased shares and reducing registered capital, and another about increasing the estimated amount of related party transactions for 2024. The content is focused on the preparation and information for a shareholders' meeting, including voting procedures and legal compliance, rather than the results of the meeting or a report of the meeting outcomes. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting. The document length is 7682 characters, which is substantial and contains detailed meeting materials, not just a brief announcement or voting results. Therefore, the correct classification is AGM Information (AGM-R).
2024-11-13 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.